AFP and neoplasm: Subsequent multivariate analysis revealed that combined LRTs modality with sorafenib remained as the independent predictor for the better PFS (adjusted HR 0.6, 95% CI 0.4–0.9, P = 0.025), together with Child-Pugh class (adjusted HR 1.4, 95% CI 1.1–1.9, P = 0.029), tumor size (adjusted HR 1.6, 95% CI 1.1–2.4, P = 0.012), EHS and/or RNI (adjusted HR 1.7, 95% CI 1.2–2.4, P < 0.001 ), AFP level (adjusted HR 1.9, 95% CI 1.4–2.5, P < 0.001), and the cumulative dose of sorafenib (transformed by natural logarithm) (adjusted HR 0.6, 95% CI 0.5–0.7, P < 0.001) (Table 2).